NRx Pharmaceuticals, Inc.

NRXP is overvalued

NASDAQ · Healthcare

FAIR PRICE

10.4%downside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

$3.56

MARKET PRICE

$3.19

FAIR PRICE

$0.37

MARGIN

UNDERFAIROVER

COMMUNITY BUY ZONE

UNLOCKS AT 10

Where does the market buy NRXP?

No one has priced NRXP yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.

COMMUNITY MEDIAN

▓▓▓▓▓

BUYERS AT TODAY'S PRICE

▓▓ %

0/10 INVESTORS · 10 MORE TO UNLOCK

METRICS

P/E
P/B
P/S18.1
PEG
DIV YIELD
ROE
ROIC-1855.5%
NET MARGIN-691.8%
DEBT/EQ
FCF YIELD-33.6%
MKT CAP$62M

NOW AVAILABLE

Get notified when NRXP's fair price changes

Push notifications when NRXP's valuation shifts. Available on iOS and Android.

Download on the App StoreGet it on Google Play

FPI RATING

0.0/ 10

Challenges include weak profitability margins and elevated debt levels.

Analytical data, not an investment recommendation. Updated daily.

How we calculate this ↗

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$2.55CONSERVATIVE ENTRY
$3.19FAIR PRICE
$3.56MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$2.55

Fair price × 0.80

DISTANCE

28.3%

Price to entry level

At the current price of $3.56, NRXP trades 28.3% above the conservative entry level of $2.55. This entry level represents a 20% margin of safety below the calculated fair price of $3.19 — a buffer that accounts for estimation uncertainty in the valuation model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

SYNCING FEED

P/E RATIO HISTORY

SYNCING FEED

METHODOLOGY

How we calculate NRXP's fair price

NRx Pharmaceuticals, Inc.'s fair price of $3.19 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $3.56, NRXP trades 10.4% above its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting NRXP's risk profile.

RELATIVE · 30%

Comparing NRXP's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for NRXP, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate NRXP's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for NRXP.

Explore on Bulios

FAQ

What is the fair price of NRXP?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for NRx Pharmaceuticals, Inc. is $3.19. At the current market price of $3.56, NRXP trades 10.4% above its calculated fair value.

Is NRXP overvalued or undervalued?+

NRx Pharmaceuticals, Inc. is currently overvalued based on our valuation model. The stock trades at $3.56, which is 10.4% above the fair price of $3.19.

What is the margin of safety for NRXP?+

With a 20% margin of safety applied to the fair price of $3.19, the conservative entry level for NRXP is $2.55. At the current market price of $3.56, the stock trades 28.3% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is NRXP's fair price updated?+

We update fair price calculations for NRXP daily after market close. The current fair price of $3.19 incorporates the latest market data and sector multiples.

What factors affect NRXP's fair price calculation?+

NRXP's fair price of $3.19 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)..

Is NRXP a good buy right now?+

At $3.56, NRXP trades 10.4% above our fair value estimate of $3.19. The stock is currently overvalued. Fair Price Index provides valuation data — always do your own research before investing.

Does NRXP pay dividends?+

NRXP does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.